Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-5829 in advanced breast cancer
NCT02983604Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Jan 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alobresib in breast cancer, sponsored by Gilead Sciences. Started Jan 2017; status: terminated.
02
Drugs
alobresib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02983604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02983604.